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Eanolazine Is Effective
or Acute or Chronic Ischemic
ysfunction With Heart Failure
e congratulate Morrow et al. (1) for their interesting study on the effects
f ranolazine in patients with non–ST-segment elevation myocardial
nfarction. Ranolazine reduced the composite primary end point of
ardiovascular death, myocardial infarction, and recurrent ischemia in
atients with B-type natriuretic peptide 80 pg/ml. Interestingly, there
as a decrease in composite arrhythmia end points consisting of ventric-
lar tachycardia (100 beats/min for 3 beats), supraventricular tachy-
ardia (120 beats/min for4 beats), and bradycardia (40 beats/min,
ause 2.5 s or 3o atrioventricular block). Ranolazine usage showed a
rend toward reduction across all arrhythmia types: ventricular tachycardia
p 0.13), supraventricular tachycardia (p 0.001), atrial fibrillation
p  0.4), and sudden cardiac death (p  0.11). These effects were
bserved over a mean duration of 343 days.
We recently reported successful use of ranolazine in a patient with
hronic ischemic cardiomyopathy, symptomatic premature ventricular
omplexes (PVC [36% of all beats]), and monomorphic ventricular
achycardia who had failed amiodarone and mexilitine therapy.
anolazine decreased the total number of PVCs to 1% to 2% of all
eats, eliminated the ventricular tachycardia, and led to complete
esolution of symptoms (2).
Inhibition of the late sodium current (INa) is the proposed
echanism of both the anti-ischemic and anti-arrhythmic benefits of
anolazine. Activity in late INa activity is increased significantly in
schemia as well as congestive heart failure (3). Increased late INa
ctivity produces higher intracellular sodium, which results in calcium
verload through the sodium-calcium exchange. Ranolazine inhibits
ate INa 10-fold more selectively than peak INa. This mechanism,
long with its 1, 2, and calcium-channel antagonism, produces its
nti-ischemic and antiarrhythmic benefits (3).
The present study shows beneficial effects of ranolazine in the setting
f acute ischemia with evidence of heart failure. Our patient had a chronic
schemic cardiomyopathy with severe myocardial dysfunction (ejection
raction 15%) for which ranolazine produced excellent symptomatic relief.
uture studies using ranolazine are needed to evaluate patients with acute
nd chronic ischemia in the presence of elevated B-type natriuretic
eptide/left ventricular dysfunction to further clarify its benefits. It
ay be this category of patients who have the highest risk–benefit
atio from ranolazine therapy.
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e appreciate the compliment and additional perspective from
r. Nanda and colleagues regarding our paper (1). Patients with
schemic heart disease and left ventricular dysfunction, such as the
atient described by Dr. Nanda and colleagues, are at substantial
isk of major cardiovascular events, including sudden cardiac death.
oreover, they are at higher risk of proarrhythmia than patients
ith normal left ventricular function with multiple classes of
ntiarrhythmic medications, and they may poorly tolerate anti-
schemic medications with negative inotropic effects. We have also
bserved that patients with elevated levels of B-type natriuretic
eptide are at particularly high risk of sudden cardiac death, even
fter accounting for left ventricular ejection fraction (2).
In pre-clinical studies, ranolazine has shown potentially favor-
ble electrophysiological effects, such as a decrease in dispersion of
epolarization, a reduction in action potential duration, and sup-
ression of early after-depolarizations (3). In addition, in animal
odels of heart failure, ranolazine improves contractile function
mmediately after acute ischemia (4) and left ventricular ejection
raction in the setting of chronic ischemic heart failure (5).
We have shown previously that in patients with unstable ischemic
eart disease, ranolazine significantly reduces the risk of ventricular
nd supraventricular tachycardia (3). Notably, we have also found that
hese effects on arrhythmias are present in patients at higher risk for
achyarrhythmia, such as those with elevated B-type natriuretic
eptide (1) or a history of left ventricular dysfunction (3). These
ndings are consistent with the observations described by Dr. Nanda
nd colleagues. On the basis of these collective findings, we agree that
he investigation of ranolazine in patients with ischemic heart disease
nd left ventricular dysfunction would be of substantial interest.
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